August 25, 2017 / 12:07 PM / 4 months ago

BRIEF-Regenxbio to acquire Dimension Therapeutics

Aug 25 (Reuters) - Dimension Therapeutics Inc

* Regenxbio to acquire Dimension Therapeutics

* Dimension Therapeutics inc - deal for ‍$3.41 per share​

* Dimension Therapeutics Inc says ‍boards of directors of both companies have unanimously approved transaction​

* Dimension shareholders will receive 0.1573 shares of Regenxbio in exchange for each of their shares in Dimension

* Dimension Therapeutics Inc - ‍ind application is anticipated to be filed for DTX201 in early 2018​

* Dimension Therapeutics Inc - ‍Regenxbio will acquire DTX201 for treatment of hemophilia A. DTX201​

* Dimension shareholders are expected to own approximately 10.9% percent of combined entity

* Dimension Therapeutics - co will, following consummation of acquisition, become a wholly owned subsidiary of Regenxbio​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below